HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Sertaconazole
SERTACONAZOLE · Sertaconazole nitrate · eno · (RS)-1-(2-((7-chloro-1-benzothiophen-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl) -1H-imidazole · Zalain · FI-7056 · fi-7045 · Dermofix
Identifikatoren & physikalische Daten
| CAS No. | 99592-32-2 |
|---|---|
| Summenformel | C20H15Cl3N2OS |
| Durchschnittliche Molmasse | 437,8 g/mol |
| Monoisotopische Masse | 435,99706714 g/mol |
| SMILES | Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |
| InChIKey | JLGKQTAYUIMGRK-UHFFFAOYSA-N |
| PubChem CID | 65863 |
| ChEMBL | CHEMBL1201196 |
| ChEBI | CHEBI:83682 |
| EC No. | 841-355-9 |
| DTXSID | DTXSID0048551 |
Chemische & physikalische Eigenschaften
| XLogP | 6,3 |
|---|---|
| Polarare Oberfläche (TPSA) | 55,3 |
| H-Brücken-Donoren | 0 |
| H-Brücken-Akzeptoren | 3 |
| Frei drehbare Bindungen | 6 |
| Schwere Atome | 27 |
| Formalladung | 0 |
| Komplexität | 488 |
| Arzneimittel | Pharmaceuticals |
| LogP (Verteilungskoeffizient) | 6.2 |
| Löslichkeit | Practically insoluble6.37e-03 g/LDMSO (Slightly), Methanol (Slightly) |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| Physical Description | Solid |
| Schmelzpunkt | 146-147° |
| Siedepunkt | 614.1±55.0 °C(Predicted) |
| Dichte | 1.43±0.1 g/cm3(Predicted) |
| Lagerbedingungen | Refrigerator |
| Aggregatzustand | Solid |
| pKa (Säurekonstante) | 6.68±0.12(Predicted) |
| Farbe | White to Pale Yellow |
| InChI | InChI=1S/C20H15Cl3N2OS/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22/h1-8,11-12,19H,9-10H2 |
| InChIKey | JLGKQTAYUIMGRK-UHFFFAOYSA-N |
| SMILES | C1N(CC(OCC2=CSC3=C(Cl)C=CC=C32)C2=CC=C(Cl)C=C2Cl)C=CN=1 |
| CAS Datenbank | 99592-32-2(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Skin Irrit. 2 (100%) |
| Expositionspfade | Bioavailability is negligible. |
| Toxizitätsübersicht | Sertaconazole interacts with 14-&alphademethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Sertaconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis. |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Alarmwort | Warnung |
| Gefahrenhinweise | Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H315 |
Anwendungen & Verwendung
Beschreibung
Sertaconazole has been developed and launched for the treatment of dermatological fungal infections by Ferrer Internacional S. A. Mylan received FDA approval for sertaconazole nitrate cream for the treatment of athlete's foot (tinea pedis) at the end of 2003.
Verwenden
An imidazole antifungal agent, inhibits the synthesis of ergosterol, an essential cell wall component of fungi.